Tofacitinib in Combination With Conventional Disease‐Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis: Patient‐Reported Outcomes From a Phase III Randomized Controlled Trial

Lignende værker

• Tofacitinib versus methotrexate in rheumatoid arthritis: patient-reported outcomes from the randomised phase III ORAL Start trial
  af: Strand, Vibeke, et al.
  Udgivet: (2016)
• Effects of tofacitinib monotherapy on patient-reported outcomes in a randomized phase 3 study of patients with active rheumatoid arthritis and inadequate responses to DMARDs
  af: Strand, Vibeke, et al.
  Udgivet: (2015)
• Efficacy and safety of tofacitinib in patients with active rheumatoid arthritis: review of key Phase 2 studies
  af: Fleischmann, Roy, et al.
  Udgivet: (2016)
• Tofacitinib or adalimumab versus placebo: patient-reported outcomes from a phase 3 study of active rheumatoid arthritis
  af: Strand, Vibeke, et al.
  Udgivet: (2016)
• Brief Report: Remission Rates With Tofacitinib Treatment in Rheumatoid Arthritis: A Comparison of Various Remission Criteria
  af: Smolen, Josef S., et al.
  Udgivet: (2017)